Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Company Research
Source: GlobeNewswire
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of schizophrenia Current data package highlights long-term safety profile, broad-spectrum clinical activity, and favorable adherence observed to date for once daily brilaroxazine over up to one year Initiation of RECOVER-2 registrational trial planned in H1 2026, subject to sufficient financing CUPERTINO, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding brilaroxazine, a
Show less
Read more
Impact Snapshot
Event Time:
RVPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RVPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RVPH alerts
High impacting Reviva Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
RVPH
News
- Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia [Yahoo! Finance]Yahoo! Finance
- Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.MarketBeat
- Reviva Pharmaceuticals: Brilaroxazine Seems Efficacious, But Progress Is Slow And Dilution Is High [Seeking Alpha]Seeking Alpha
- Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
RVPH
Earnings
- 11/13/25 - Beat
RVPH
Sec Filings
- 12/23/25 - Form 8-K
- 12/22/25 - Form SCHEDULE
- 12/19/25 - Form 4
- RVPH's page on the SEC website